Affiliation:
1. *Molecular Genetics and Biochemistry and
2. ‡Megabios, Burlingame, CA 94010; and
3. §GenVec, Rockville, MD 20852
4. †Orthopaedic Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA 15261;
Abstract
Abstract
IL-10, a cytokine produced primarily by macrophages, B lymphocytes, and Th2 cells, has both immunostimulatory and immunosuppressive properties. A homologue of IL-10 encoded by EBV, known as viral IL-10 (vIL-10), is also able to suppress the immune response, but may lack some of the immunostimulatory properties of IL-10. To evaluate the potential of vIL-10 to block the progression of rheumatoid arthritis, we have utilized a replication-defective adenovirus vector to deliver the gene encoding vIL-10 to the knee joints of rabbits with Ag-induced arthritis. Intraarticular expression of vIL-10 significantly reduced leukocytosis, cartilage matrix degradation, and levels of endogenous rabbit TNF-α, as well as the degree of synovitis, while maintaining high levels of cartilage matrix synthesis. Interestingly, an antiarthritic effect was also observed in opposing contralateral control knee joints that received only a marker gene. An adenoviral vector carrying the enhanced green fluorescent protein marker gene was used to demonstrate that a morphologically similar subset of cells infected in the injected knee joint are able to traffic to the uninjected contralateral knee joint. Our results suggest that direct, local intraarticular delivery of the vIL-10 gene may have polyarticular therapeutic effects.
Publisher
The American Association of Immunologists
Subject
Immunology,Immunology and Allergy
Reference41 articles.
1. Moreland, L W., L. W. Heck, Jr, W. J. Koopman. 1997. Biologic agents for treating rheumatoid arthritis: concepts and progress. Arthritis Rheum. 40: 397
2. Moreland, L. W., G. R. Margolies, L. W. Heck, P. A. Saway, C. Blosch, R. Hanna, W. J. Koopman. 1996. Recombinant soluble tumor necrosis factor receptor (p80) fusion protein: toxicity and dose finding trial in refractory rheumatoid arthritis. J. Rheumatol. 23: 1849
3. Arend, W. P., M. Malyak, M. F. Smith, Jr, T. D. Whisenand, J. L. Slack, J. E. Sims, J. G. Giri, S. K. Dower. 1994. Binding of IL-1α, IL-1β and IL-1 receptor antagonist by soluble IL-1 receptors and levels of soluble IL-1 receptors in synovial fluids. J. Immunol. 153: 4766
4. Arend, W.P.. 1993. Interleukin-1 receptor antagonist. Adv. Immunol. 54: 167
5. Elliot, M. J., R. N. Maini, M. Feldmann, J. R. Kalden, C. Antoni, J. S. Smolen, B. Leeb, F. C. Breeveld, J. D. Macfarlane, H. Bijl. 1994. Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor α (cA2) versus placebo in rheumatoid arthritis. Lancet 344: 1105
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献